Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2013
15th World Conference on Lung Cancer
Access to all presentations that occurred during the 15th World Conference on Lung Cancer in Sydney, Australia.
Presentation Date(s):- October 27 - 30, 2013
- Total Presentations: 2517
-
+
P1.10 - Poster Session 1 - Chemotherapy
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 57
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.10-037 - A retrospective comparison of adjuvant chemotherapeutic regimen for non-small cell lung cancer (NSCLC): Paclitaxel plus platinum versus Vinorelbine plus Cisplatin
09:30 - 09:30 | Author(s): W.J. Chang
- Abstract
Loading...
-
+
MO07 - NSCLC - Targeted Therapies II
- Type: Mini Oral Abstract Session
- Track: Medical Oncology
- Presentations: 14
- Moderators:T. John
- Coordinates: 10/28/2013, 16:15 - 17:45, Bayside Auditorium B, Level 1
-
+
MO07.02 - Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases in PROFILE 1005 and PROFILE 1007
16:20 - 16:25 | Author(s): D.B. Costa
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MO07.14 - DISCUSSANT
17:30 - 17:40 | Author(s): M. Ahn
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MO10 - Molecular Pathology II
- Type: Mini Oral Abstract Session
- Track: Pathology
- Presentations: 13
- Moderators:W.A. Franklin
- Coordinates: 10/28/2013, 16:15 - 17:45, Bayside 104, Level 1
-
+
MO10.01 - Integrative and comparative genomic analysis of East-Asian lung squamous cell carcinomas
16:15 - 16:20 | Author(s): Y. Kim
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.11 - Poster Session 2 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 46
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.11-030 - Is there any predictor for clinical outcome in EGFR mutant
NSCLC patients treated with EGFR TKIs ?09:30 - 09:30 | Author(s): J.Y. Lee
- Abstract
Loading...
-
+
P2.12 - Poster Session 2 - NSCLC Early Stage
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 23
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.12-018 - Brain metastases as a first site of recurrence in surgically resected non-small-cell lung cancer
09:30 - 09:30 | Author(s): W.J. Chang
- Abstract
Loading...
-
+
P2.22 - Poster Session 2 - Epidemiology, Etiology
- Type: Poster Session
- Track: Prevention & Epidemiology
- Presentations: 13
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.22-003 - BIM (BCL2L11) deletion polymorphism is one of major risk factors of Lung cancer in Korean population.
09:30 - 09:30 | Author(s): E.N. Cho
- Abstract
Loading...
-
+
O18 - Cancer Control and Epidemiology II
- Type: Oral Abstract Session
- Track: Prevention & Epidemiology
- Presentations: 8
- Moderators:M.R. Spitz
- Coordinates: 10/29/2013, 10:30 - 12:00, Bayside 103, Level 1
-
+
O18.02 - Impacts of environmental tobacco smoke on EGFR mutations and ALK rearrangements in never smokers with non-small cell lung cancer: Analyses on a prospective multinational ETS registry
10:40 - 10:50 | Author(s): A. Kubo
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
O21 - SCLC II
- Type: Oral Abstract Session
- Track: Medical Oncology
- Presentations: 8
- Moderators:M. Ahn
- Coordinates: 10/29/2013, 16:15 - 17:45, Parkside Ballroom B, Level 1
-
+
O21.01 - A multicenter phase III randomized double-blind placebo controlled trial of pravastatin added to first-line standard chemotherapy in patients with small cell lung cancer (SCLC)
16:15 - 16:25 | Author(s): M.J. Seckl
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
O21.02 - Phase III trial comparing irinotecan plus cisplatin (IP) with etoposide plus cisplatin (EP) in Korean patients with extensive disease (ED) small cell lung cancer (SCLC)
16:25 - 16:35 | Author(s): D. Kim
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
O21.03 - N-0923, A randomized double-blind phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: Alliance (NCCTG) Study
16:35 - 16:45 | Author(s): A. Adjei
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
O21.04 - DISCUSSANT
16:45 - 17:00 | Author(s): N. Murray
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
O21.05 - A multicenter, double-blind, placebo-controlled, randomized phase 2 study of ganitumab or rilotumumab with platinum-based chemotherapy as first-line treatment for extensive-stage small-cell lung cancer (SCLC)
17:00 - 17:10 | Author(s): B. Glisson
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
O21.06 - MLN8237 (alisertib), a selective Aurora A Kinase (AAK) inhibitor, in patients with relapsed/refractory small cell lung cancer (SCLC): Phase 2 results
17:10 - 17:20 | Author(s): L. Havel
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
O21.07 - A new prognostic model for relapsed/refractory extensive stage small cell lung cancer (ES-SCLC) derived from prospective SWOG trials: implications for study design
17:20 - 17:30 | Author(s): P. Lara
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
O21.08 - DISCUSSANT
17:30 - 17:45 | Author(s): K. Kelly
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P3.06 - Poster Session 3 - Prognostic and Predictive Biomarkers
- Type: Poster Session
- Track: Biology
- Presentations: 53
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.06-004 - T790M Mutation in Patients with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Is It Associated with Clinically Distinct Features?
09:30 - 09:30 | Author(s): J.H. Ji
- Abstract
Loading... -
+
P3.06-008 - Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): D.W. Hwang
- Abstract
Loading...
-
+
P3.09 - Poster Session 3 - Combined Modality
- Type: Poster Session
- Track: Combined Modality
- Presentations: 18
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.09-013 - Outcomes and predictors for recurrence and survival after neoadjuvant concurrent chemoradiation followed by operation in patients with clinical stage III-N2 non-small-cell lung cancer
09:30 - 09:30 | Author(s): H. Lim
- Abstract
Loading... -
+
P3.09-015 - The role of adjuvant treatment in N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiation followed by surgery: A retrospective single center experience.
09:30 - 09:30 | Author(s): J.Y. Hong
- Abstract
Loading...
